Current Report Filing (8-k)
November 14 2016 - 6:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported
)
November 12,
2016
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
333-143570
|
36-4296006
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
4203 SW 34
th
St.
|
|
Orlando,
FL
|
32811
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
On November 12, 2016, the Board of Directors (the
“Board”) of MEDITE Cancer Diagnostics, Inc. (the
“Company”) held a meeting whereby it appointed our
Chief Executive Officer, David E, Patterson, to the position of
Chief Financial Officer/Treasurer/Secretary to serve on an interim
basis until a suitable permanent replacement is
appointed.
Item 9.01
Financial
Statements and Exhibits
None
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
Date:
November 14, 2016
|
By:
|
/s/ David Patterson
|
|
|
David
Patterson
|
|
|
Chief
Executive Officer
|
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medite Cancer Diagnostics (CE) (USOTC:MDIT)
Historical Stock Chart
From Sep 2023 to Sep 2024